Intellia Therapeutics is rated a Buy due to two major gene therapy developments: Lonvo-Z for hereditary angioedema (HAE) and Nex-Z for ATTR amyloidosis. Lonvo-Z's Phase 3 trial showed an 87% reduction in attacks but faced muted market response due to safety and competition concerns. The FDA has lifted clinical holds on Nex-Z, allowing progress in a $16.8 billion ATTR market with a unique one-time treatment. Intellia's $517 million cash supports Lonvo-Z's launch, though ongoing losses may require more fundraising. Long-term success depends on market acceptance and regulatory approvals.
Taiwan Semiconductor Manufacturing Company (TSMC) reported a 23.4% increase in second-quarter profit from the previous quarter, surpassing analyst estimates. The company's net income reached NT$706.56 billion ($39.45 billion), a record high for the f...
National Beverage faces stagnant growth as LaCroix volumes have declined for four straight years, reducing brand excitement. The stock trades at reasonable multiples reflecting muted growth and no clear catalysts for upside. Despite stable gross marg...
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
A bitcoin wallet that had been inactive since 2017 moved its entire holding of 5,908 BTC, now worth about $383 million, to a new, unidentified address. The coins were originally bought near bitcoin's 2017 peak at around $16,000 each and have gained r...
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
